‹ All Posts
Clovek Advisory

20th Oct · SEBI Registration INA100014879

Board approve enabling resolution explore raising upto 600Cr

ORCHPHARMA 's Board met on October 20, 2026 and approved an enabling resolution to explore options for raising funds. Indicative size: up to Rs. 600 Crores (Rupees Six Hundred Crore Only). Possible routes: equity shares, other eligible securities or instruments, fully or partly convertible debentures, QIP, private placement, public issue of equity shares and/or debt securities, preferential issue or any ***** to statutory and regulatory approvals, and member approval where ***** filing states the required information is not available as on date. Size vs market cap: Rs 600 crore is ~11.2% of the stated market cap (Rs 5,351 cr), so a material capital raise but not a takeover-size event. Dilution risk: a primary-equity route at market prices could dilute existing shareholders by roughly the same order (single-digit to low-double-digit %), depending on issuance method and pricing. Promoter control: promoters hold 74.45% — preferential/private placement to promoters or allotment with promoter participation would preserve control but could further entrench promoter share; an open QIP or public issue would dilute promoter/public proportions depending on participation. Balance sheet/leverage trade-off: current debt-to-equity is low (0.2x). Raising the full amount as debt would materially increase leverage and financial risk, while equity issuance would conserve leverage but dilute earnings per share.

#WatchOutFor#StockInNews#EquityResearch#MacroViews#FundamentalViews
1,020 likes·68 comments